Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1680
    +0.0023 (+0.20%)
     
  • GBP/USD

    1.2498
    -0.0013 (-0.10%)
     
  • Bitcoin GBP

    51,113.28
    -615.83 (-1.19%)
     
  • CMC Crypto 200

    1,329.13
    -67.40 (-4.82%)
     
  • S&P 500

    5,099.81
    +51.39 (+1.02%)
     
  • DOW

    38,239.13
    +153.33 (+0.40%)
     
  • CRUDE OIL

    83.65
    +0.08 (+0.10%)
     
  • GOLD FUTURES

    2,350.60
    +8.10 (+0.35%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

Alexion: Analysts Raise Their Target Prices

Alexion: Analysts Raise Their Target Prices

Alexion Pharmaceuticals (ALXN) is one of the leading biotechnology firms. Soliris is approved to treat aHUS (atypical hemolytic uremic syndrome) and PHN (paroxysmal nocturnal hemoglobinuria). Alexion’s latest acquisition of Wilson Therapeutics is a turnaround strategy that’s being implemented to restructure Alexion’s performance and investors’ sentiments in the market.